0
Orphan Designations
1
FDA Approvals
Latest: SUBVENITE (2025)
0
Active Trials
200 recruiting
2
Rare Diseases
across 2 areas
0
News (30d)
Quiet
OWP Pharmaceuticals, Inc. is a company with 0 orphan drug designations across 2 rare diseases, including 1 FDA-approved therapy. 4 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| bipolar I disorder | SUBVENITE | Des.TrialAppr. |
| epilepsy | SUBVENITE | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
4
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
4
affecting portfolio